Positiv
●
Seeking Alpha
●
vor 5 Monaten
Hoffman-La Roche aka Roche Holding AG delivered robust 2025 results, with core EPS up 11% CER and a resilient pharma division driving growth. RHHBY's pipeline, especially in obesity and cardiovascular, positions it as a potential third major player in the GLP-1 market. Management guides for mid-single digit sales and high-single digit core EPS growth in 2026, alongside a dividend increase.